News

Proteostasis to Present Early Data from Phase 1 Study of Potential CF Therapy at NACFC Meeting

Proteostasis Therapeutics announced it will present preliminary data from its ongoing Phase 1 clinical trial evaluating ascending doses of PTI-428, an oral treatment for people with cystic fibrosis (CF). The data will be presented at the 30th Annual North American Cystic Fibrosis Conference (NACFC 2016), taking place Oct. 27–29 in Orlando, Florida.

Corbus to Give Update on Phase 2 Study of Resunab at CF Summit

Corbus Pharmaceuticals announced that its CEO will give an update on clinical work and anticipated milestones for Resunab (JBT-101), the company’s synthetic oral drug designed to resolve chronic inflammation and fibrosis, at the upcoming Jefferies Cystic Fibrosis Summit. The treatment is under evaluation in three Phase 2 clinical trials. Last year, Corbus received…